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hormone insufﬁ  ciency
There is consensus among practitioners of age-management/longevity medicine that 
progressive failure of neuroendocrine function leads to hormone insufﬁ  ciency, which 
underlies many of the maladaptive consequences of aging. Accordingly, one of the most 
commonly employed clinical interventions in aging is balanced hormone replacement 
therapy (HRT). This approach is often quite effective since many of the structural and 
functional consequence of aging result at least in part from inadequate endogenous hor-
mone supply and/or imbalance of multiple hormone actions upon the body. However, 
while HRT is effective in opposing many of the more obvious degenerative effects 
of aging on body composition and function it does little to treat the pathophysiologi-
cal factors underlying neuroendocrine decline. In fact, HRT may actually accelerate 
senescence of neuroendocrine elements within the brain and pituitary gland. 
Growth hormone replacement therapy (GHRT) which has been the cornerstone of 
age-management HRT for many years provides a familiar example of this paradox. 
The basis for prescribing recombinant growth hormone (hGH) to sustain health dur-
ing aging derived from observation of young adults who received hGH as children 
to treat short stature. Once those children reached their ﬁ  nal height, GHRT was dis-
continued because hGH was thought necessary only to stimulate growth. However, it 
soon became apparent that growth hormone deﬁ  ciency (GHD) in these young adults 
had signiﬁ  cant negative consequences on their health and vitality. Such individuals 
experienced increased risk for development of life threatening disorders such as high 
blood pressure, diabetes, cardiovascular disease and cancer. Signiﬁ  cant to practitioners 
of age-management medicine was the fact that these diseases also typically occur in 
normal adults during middle age and later. Coincidentally, growth hormone produc-
tion and secretion declines progressively with advancing age, and that such change 
correlates with increased risk for the same intrinsic diseases observed in GHD young 
adults. However, it also became apparent in older adults receiving hGH that the hor-
mone had biphasic effects in which overdosing produced many of the same symptoms 
as deﬁ  ciency, eg, hyperglycemia, increased blood pressure, etc. These effects were 
attributed not only to over dosage, but also to the unnatural, pharmacological presen-
tation of the hormone resulting from bolus administration. Because hGH metabolic 
dynamics is controlled by a feedback network consisting of stimulatory and inhibitory 
elements, its normal physiological pattern of release from the pituitary is episodic. 
In contrast, an injection of hundreds of micrograms and even milligrams of hormone 
produces a “square wave” that not only has the potential for down-stream receptor 
saturation, but also up-stream distortion of normal feedback relationships. For example, 
hyper-exposure to GH inhibits transcription of growth hormone releasing hormone 
(GHRH) mRNA while stimulating that of somatostatin (Bertherat et al 1993). This 
combined feedback effect causes down-regulation of pituitary GHRH receptors and 
“disuse atrophy” of the pituitary gland which actually accelerates the age associated 
decline in its ability to produce hGH (Horikawa et al 1996). 
Hypothalamic catecholaminergic and indolaminergic neurons control hGH produc-
tion and secretion (Blackard and Heidingsfelder 1968) presumably by affecting GHRH 
and somatostatin neurosecretory neuron activity, respectively. Thus, suppression of Clinical Interventions in Aging 2007:2(4) 496
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catecholaminergic neuronal activity by negative feedback 
from exogenous hGH may contribute further to the global 
cascade of neuroendocrine failure associated with advanc-
ing age. Thus, while end-product HRT may be effective 
in opposing certain aspects of somatic senescence, it fails 
to simulate youthful endocrine physiology, has a potential 
for overdosing and may actually accelerate neuroendocrine 
senescence.
A novel approach to gaining the beneﬁ  ts of HRT with-
out compromising youthful, physiological function within 
the neuroendocrine system is called PLI therapy. PLI is an 
acronym for Primary Locus Intervention which is so named 
because it targets the progressive, age-related decline in 
hormone production at the highest neuroendocrine level of 
organization. Unlike end-product HRT, the objective of PLI 
therapy is to restore feedback and other normal physiological 
relationships within the brain-neuroendocrine complex and 
thereby to restore youthful endogenous hormone production/
secretion. The intervention is based upon the observation that 
dopamine receptors decline in the human brain with aging 
(Wong et al 1997) and the idea that age-distortion of cat-
echolamine (norepinephrine and dopamine) and indoleamine 
(serotonin) neurotransmitter dynamics is a higher order, if not 
primary neuroendocrine defect. This concept is supported 
by the fact that dopamine and norephinephrine are known 
to promote release of pituitary hormones including GH and 
gonadotropins (Blackard and Heidingsfelder 1968; Mohan-
dumar et al 1994). During aging, steady state concentrations 
and turnover of these catecholamines in hypothalamic regions 
responsible for control of pituitary function are signiﬁ  cantly 
reduced compared to youth while relative concentrations of 
serotonin increase (Simpkins et al 1977). Presumably, such 
imbalance leads to inhibitory serotonin dominance These 
changes may contribute at least in part to the age-related 
decline in pituitary hGH and other hormones. For example, 
when catecholaminergic neurotransmission was speciﬁ  cally 
blocked with drugs, hGH release was reduced. However, this 
neurotransmitter defect was not irreversible. When catechol-
amine activity was restored after pharmacological blockade, 
youthful hGH production and secretion also increased. Cate-
cholamine neurotransmitters were increased by administration 
of precursors which in turn increased pituitary/serum growth 
hormone concentrations, restored youthful episodic patterns 
of secretion (Sonntag et al 1982) promoted its anabolic effects 
upon the body (Sonntag et al 1985) and extended life (Cotzias 
et al 1974). Similarly, monoamine oxidase (MAO) inhibitors 
which reduced catecholamine turnover also improved neu-
roendocrine function and extended life (Cotzias et al 1974; 
Ruehl 1997). The fact that these treatments extended life 
may be attributed to their ability to reduce intrinsic disease, 
which is known to increase in hormone deﬁ  cient individuals 
(such as those suffering GHD or multiple pituitary hormone 
deﬁ  ciency). Support for this premise derives from a carcino-
genicity research study in which long term administration of 
a dopaminergic compound signiﬁ  cantly reduced seven neo-
plastic lesions, ﬁ  ve nonneoplastic lesions and prevented two 
age-related, degenerative somatic changes in treated subjects 
(Walker et al 1998). 
Although supporting evidence for PLI therapy has been 
available for several decades, it has not been widely used in 
clinical settings because no single product or line of products 
has yet been created for general application in age-manage-
ment medicine. This is understandable because the many 
choices of potentially efﬁ  cacious compounds make selecting 
one or another somewhat difﬁ  cult without specialty training. 
However, this fact should not create an impenetrable barrier 
to testing the potential of PLI therapy as a more effective, 
safer and legal method for treating age-associated hormone 
deﬁ  ciency than end-product HRT. Surely physiological 
rejuvenation of the complete neuroendocrine system would 
be a better alternative than pharmacological replacement 
of exogenous hormones. This alternative has actually been 
available for many years in the form of herbal supplements 
that are rich in neurotransmitter precursors and monoamine 
oxidase inhibitors even though they are not restricted by laws 
governing prescriptions drugs. Some of these compounds 
include: 
•  Mucuna pruriens which provides catecholamine and 
acetylcholine precursors
•  Lycium chinense, Uncaria rhynchophylla, and Ginkgo 
biloba which contains monoamine oxidase inhibitors 
•  Dimethylaminoethanol which is an acetylcholinesterase 
inhibitor having the potential to increase brain acetylcho-
line
•  Lepidium meyenii or Maca which directly stimulates 
production of important pituitary hormones and
•  Many other commercially available compounds including 
somatostatin inhibitory amino acids and antioxidants to 
support cellular membrane integrity 
Since we as practitioners of age-management medicine 
are constantly seeking new and improved methods for bring 
better health, vitality and longer life to our clients, perhaps 
PLI therapy will be a valuable complement to currently em-
ployed interventions in aging. I invite your feedback to this 
suggestion hoping to stimulate interest in developing such 
new methodologies.Neuropsychiatric Disease and Treatment 2007:2(4) 497
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